Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced/metastatic breast cancer.~* HER2-expressing primary or metastatic tumor~* Two prior regimens with HER2. Trastuzumab must have been given. No limit to prior therapies~* Measurable disease with RECIST 1.1~* Clinical progression~* LVEF WNL~* ECOG 0 or 1~* Last dose of chemotherapy, radiotherapy, surgery, ablative therapy, tyrosine kinase inhibitor, ≥2 weeks~* Administration of biological therapy ≥4 weeks~* Last dose of trastuzumab must be ≥1, or ≥3 weeks prior to start, if previously administered on an every 3 week schedule.~* Resolution of toxic effects to baseline or Grade 1, except alopecia (NCI CTCAE Version 3.0~* Organ and marrow function:~  * Hemoglobin ≥8.0 g/dL~ * ANC ≥1200/µL~ * Platelets ≥75,000 /µL~ * ALT and AST ≤ 1.5 x ULN~ * Alkaline phosphatase ≤2.5 x ULN, or ≤3.0 x ULN if secondary to liver metastases.~ * Serum bilirubin WNL~ * Serum albumin ≥3.0 g/dL~ * PT, PTT ≤1.5 x ULN~ * Serum creatinine ≤1.5 x ULN~* Negative pregnancy test~Exclusion Criteria:~* Prior treatment with Hsp90 inhibitor.~* Grade 4 AE secondary to trastuzumab. Grade 3/4 infusion reactions or Grade 3/4 symptomatic heart failure~* Medication/food that is a CYP3A inhibitor or inducer.~* Hx 6 months: cardiac disease - acute coronary syndrome or unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident or significant co-morbid condition~* Grade 3 or 4 hemorrhagic event within 6 months.~* HIV positivity~* Baseline QT corrected, QTcF \>470 ms~* Sinus bradycardia \<50 bpm Secondary to pharmacologic therapy may enroll if stopping therapy normalizes heart rate.~* Malignancies within 3 years other than non-melanomatous skin cancers, non-muscle-invasive bladder cancer and carcinoma in situ of cervix.~* Active keratitis or keratoconjunctivitis~* Active brain metastasis (e.g., requiring therapy with steroids or radiation therapy; or with intracranial progression 4 weeks after the completion of radiation therapy) uncontrolled seizure disorder, ongoing spinal cord compression, or carcinomatous meningitis. If clinically stable brain metastasis (previously treated or untreated)are present pt is eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPI-504 and Trastuzumab (Type: EXPERIMENTAL): IPI-504 IV infusion 300 mg/m2 once weekly in combination with trastuzumab infusion every 3 weeks. (Continuous schedule)~Three week cycle with IPI-504 twice per week for 2 weeks and trastuzumab once per cycle followed by one week without treatment.~Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was \<4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.~IPI-504 and trastuzumab will be administered for all cycles. Until progression or unacceptable toxicity develops.

Based on this trial design, predict the completion outcome and termination type (if applicable).